​

CRISPR Therapeutics Ownership | Who Owns CRISPR Therapeutics?

OverviewForecastRevenueFinancialsChart

CRISPR Therapeutics Ownership Summary

CRISPR Therapeutics is owned by 73.72% institutional investors, 1.57% insiders, and 24.70% retail investors. Ark investment management is the largest institutional shareholder, holding 11.52% of CRSP shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 7.64% of its assets in CRISPR Therapeutics shares.

CRSP Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCRISPR Therapeutics73.72%1.57%24.70%
SectorHealthcare Stocks 232.86%10.65%-143.51%
IndustryBiotech Stocks 382.13%10.41%-292.54%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management10.52M11.52%$551.78M
Blackrock funding, inc. /de7.51M8.22%$393.73M
Capital investors5.89M6.45%$309.02M
Orbis allan gray4.98M5.72%$322.89M
State street4.01M4.60%$259.71M
T. rowe price investment management3.28M3.77%$212.75M
Gsk3.22M3.53%$168.89M
Blackrock2.78M3.40%$150.03M
Vanguard group2.27M2.48%$118.95M
Geode capital management2.25M2.46%$117.97M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Gsk3.22M21.14%$168.89M
Sr one capital management, lp2.04M15.14%$106.91M
Spear rsc165.00K6.29%$8.91M
Versant venture management148.83K5.01%$7.08M
Ecor1 capital1.39M4.32%$90.04M
Nea management company1.06M3.76%$68.61M
Ark investment management10.52M3.66%$551.78M
Green alpha advisors57.02K2.67%$2.71M
Contrarius investment management685.72K2.32%$37.04M
Eagle health investments lp197.00K1.87%$10.64M

Top Buyers

HolderShares% AssetsChange
Gsk3.22M21.14%3.22M
Orbis allan gray4.98M1.39%2.22M
State street4.01M0.01%736.64K
Ark investment management10.52M3.66%735.08K
Millennium management583.73K0.01%575.24K

Top Sellers

HolderShares% AssetsChange
Two sigma advisers, lp572.97K0.07%-771.73K
Ubs group1.76M0.01%-761.61K
Morgan stanley667.06K0.00%-730.80K
National bank of canada /fi/9.82K0.00%-725.78K
Baker bros. advisors lp---654.10K

New Positions

HolderShares% AssetsChangeValue
Gsk3.22M21.14%3.22M$168.89M
Vanguard fiduciary trust542.68K0.01%542.68K$25.82M
Norges bank490.21K0.00%490.21K$25.71M
Vanguard asset management76.86K0.00%76.86K$3.66M
Vanguard global advisers39.23K0.00%39.23K$1.87M

Sold Out

HolderChange
Tortoise investment management-1.00
Activest wealth management-1.00
Carolina wealth advisors-1.00
Impact partnership wealth-1.00
Frazier financial advisors-2.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025430-10.60%67,314,484-6.81%731.07%208-7.96%108-11.48%
Sep 30, 2025461-2.12%71,905,056-0.80%821.19%220-6.78%11715.84%
Jun 30, 20254579.33%72,312,35012.69%831.49%22831.03%101-2.88%
Mar 31, 202516-96.30%3,317,986-94.86%30.07%8-95.58%3-97.52%
Dec 31, 2024420-5.83%64,513,2688.48%761.57%174-118-10.61%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite7.33M7.64%99.89K
ARK Innovation ETF6.17M6.40%-450.25K
iShares Russell 2000 ETF2.15M2.23%18.09K
ARK Genomic Revolution ETF2.10M2.18%89.00K
ARK Genomic Revolution1.99M2.08%73.66K
American Funds New Perspective A1.94M2.03%-
Capital Group New Perspective Comp1.94M2.02%-
State Street® SPDR® S&P® Biotech ETF1.89M1.96%-18.73K
American Funds SMALLCAP World A1.65M1.72%-
SPDR® S&P Biotech ETF1.40M1.53%3.11K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 23, 2026KASINGER JAMES R. General Counsel and SecretarySell$148.85K
Mar 23, 2026Kulkarni Samarth Chief Executive OfficerSell$468.74K
Mar 23, 2026Prasad Raju Chief Financial OfficerSell$173.46K
Mar 16, 2026Patel Naimish Chief Medical OfficerSell$152.02K
Mar 16, 2026Prasad Raju Chief Financial OfficerSell$282.22K

Insider Transactions Trends

DateBuySell
2026 Q1-19
2025 Q4-6
2025 Q341
2025 Q2-1
2025 Q1117

CRSP Ownership FAQ

Who Owns CRISPR Therapeutics?

CRISPR Therapeutics shareholders are primarily institutional investors at 73.72%, followed by 1.57% insiders and 24.71% retail investors. The average institutional ownership in CRISPR Therapeutics's industry, Biotech Stocks , is 382.13%, which CRISPR Therapeutics falls below.

Who owns the most shares of CRISPR Therapeutics?

CRISPR Therapeutics’s largest shareholders are Ark investment management (10.52M shares, 11.52%), Blackrock funding, inc. /de (7.51M shares, 8.22%), and Capital investors (5.89M shares, 6.45%). Together, they hold 26.20% of CRISPR Therapeutics’s total shares outstanding.

Does Blackrock own CRISPR Therapeutics?

Yes, BlackRock owns 3.40% of CRISPR Therapeutics, totaling 2.78M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 150.03M$. In the last quarter, BlackRock increased its holdings by 231.42K shares, a 9.09% change.

Who is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested?

Gsk is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested, with 21.14% of its assets in 3.22M CRISPR Therapeutics shares, valued at 168.89M$.

Who is the top mutual fund holder of CRISPR Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of CRISPR Therapeutics shares, with 7.64% of its total shares outstanding invested in 7.33M CRISPR Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools